Skip to content

Investigating the therapeutic efficacy of all-trans retinoic acid in autism spectrum disorder patients with 15q11-13 duplication syndrome

Investigating the therapeutic efficacy of all-trans retinoic acid in autism spectrum disorder patients with 15q11-13 duplication syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106809
Enrollment
Unknown
Registered
2025-07-30
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dup15q syndrome

Interventions

Group younger:Oral All-Trans Retinoic Acid (ATRA)
Group elder:Oral All-Trans Retinoic Acid (ATRA)

Sponsors

The Second Affiliated Hospital of Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 7 Years

Inclusion criteria

Inclusion criteria: 1.Clinical Diagnosis ??Conducted by two experienced physicians?? based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V); 2.Diagnostic Scale Assessment ??Performed by professionally certified examiners?? using ??ADOS-2; 3.Genetic Testing ??Diagnostic criteria via genomic analysis??: detection of 15q11-13 duplication?? containing UBE3A;

Exclusion criteria

Exclusion criteria: 1.?History of acute or chronic infection within the past 3 months?; 2.Active epileptic seizures within the past 6 months?; 3.Intake of nutritional supplements (e.g., vitamin A and/or minerals) within the past 1 month?; 4.History of chronic diseases, including abnormal liver function, abnormal renal function, or thyroid dysfunction?;

Design outcomes

Primary

MeasureTime frame
ADOS-2 Score;

Countries

China

Contacts

Public ContactFeng Jianhua

The Second Affiliated Hospital of Zhejiang University School of Medicine

zeek2013@sina.com+86 571 89713747

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026